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Idiosyncratic drug-induced liver injury (IDILI) is a significant source of drug recall and acute liver failure (ALF) in the United
States. While current drug development processes emphasize general toxicity and drug metabolizing enzyme- (DME-) mediated
toxicity, it has been challenging to develop comprehensive models for assessing complete idiosyncratic potential. In this review, we
describe the enzymes and proteins that contain polymorphisms believed to contribute to IDILI, including ones that affect phase I
and phase II metabolism, antioxidant enzymes, drug transporters, inflammation, and human leukocyte antigen (HLA). We then
describe the various assays that have been developed to detect individual reactions focusing on each of themechanisms described in
the background. Finally, we examine current trends in developing comprehensive models for examining these mechanisms. There
is an urgent need to develop a panel of multiparametric assays for diagnosing individual toxicity potential.
1. Introduction
Adverse drug reactions (ADRs) are among the five leading
causes of death in the United States, with hepatotoxic events
being the most common site of ADRs, owing to the fact
that the liver is the organ associated with clearance of toxic
substances [1]. While the majority of ADRs that contribute to
acute liver failure (ALF) are considered to be dose-dependent
or “intrinsic,” roughly 10–15% of ALF can be attributed to
individual effects that are not dependent on dose [1]. These
idiosyncratic adverse drug reactions (IADRs) are responsible
for a significant amount of drug withdrawals during and after
postclinical marketing trials [1]. Additionally, the cost for
successful drug development can range from $160 million
to $1.8 billion, and it takes ten to fifteen years from lead
compound discovery to clinical evaluation [2]. This cost
increases significantly when drug candidates fail at the late
stage of clinical trials or drugs arewithdrawn from themarket
due to unexpected ADRs. With roughly a postmarketing
failure rate of one drug per year, there is a critical need to
reduce the human and fiscal cost by decreasing incidence of
IADRs.
While significant resources have been put into developing
toxicity screens, there is very little in the way of predicting
IADRs [3]. Many of the current technologies for detecting
hepatotoxicity focus on cytotoxicity screens for in vitro
hepatocyte cultures as a method to weed out drug candidates
before clinical trials [3]. Subsequent follow-up with animal
models is used to reduce the possible drug failure [4–
6]. Unfortunately, these screens often have poor predictive
value in assessing hepatotoxicity potential [7]. This problem
becomes exacerbatedwhen accounting for IADRs, asmany of
the preclinical trials focus onmodels that utilize healthy livers
with fully functioning drug metabolizing enzymes (DMEs)
[8–10].
It is believed that propensities for IADRs and IDILI
can be increased by both genetic and nongenetic factors.
Such nongenetic factors could include current disease states,
pregnancy, other drugs being simultaneously taken with the
drug causing the adverse reaction, and age [11]. Potential
genetic factors focus on polymorphisms affecting the various
DMEs, enzymes that reduce reactive oxygen species (ROS),
drug transporters, the inflammation response in the liver,
and the major histocompatibility complex (MHC) class of
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proteins [5, 11]. Aside from several of the mechanisms that
govern immune responses, all of these genetic responses can
be localized to the liver, although a few othermechanisms can
be found in other organs.
In this review, we address the basis for drug metabolism
and disposition in the liver and the proteins and enzymes
involved in these processes. We discuss any polymorphisms
that have been correlated with (and potentially causative
of) ADRs and assays that detect potential for ADRs due to
these polymorphisms. The potential mechanisms addressed
will include mutations that affect drug metabolism, drug
disposition, antioxidantmediating enzymes, and the immune
system. In addition, we will address what demographics are
most likely to contain these mutations. Next, we discuss
the various assays that can be implemented for measuring
responses associated with dysfunction in critical proteins.
Finally, we discuss the design of future platforms that can
help integrate these assays to generate a complete profile for
predicting ADRs.
2. Mechanisms for Idiosyncratic
Hepatotoxicity
The natures of ADRs are complex. While an individual can
have an adverse reaction to a drug, it is difficult to determine
the exact cause of the reaction. Many ADRs are caused by
the parent drug, the metabolized drug, or byproducts of drug
metabolism. The drug metabolism process and the potential
triggers for cellular toxicity are illustrated in Figure 1. Drug
metabolism relies on an initial transport of drug into the hep-
atocyte via influx transporters [13]. The drug is metabolized
by phase I DMEs, often creating more reactive metabolites
[14].This is followed up with modification via phase II DMEs
with a bulkier side chain to deactivate them [14]. The parent
drug, reactive metabolites, and heavier products will then all
be transported into the bile by efflux transporters compared
to those that transport the drug into the cell [13, 14]. Any
forms of the drug may produce ROS, which need to be
reduced to prevent damage to the cell [15]. Additionally, the
drug and its metabolites may conjugate to proteins, forming
haptens, which can be presented on the surface of the cell,
making it recognized by the immune systemas a damaged cell
[16]. Any polymorphism that affects drug metabolism, drug
transport, antioxidant defense, and immune responses is a
potential mechanism associated with increased risk to IDILI.
2.1. Phase I Drug Metabolizing Enzymes. Phase I metabolism
revolves around modification of the parent drug to create
reactive metabolites via formation of alcohol and aldehyde
groups (Table 1) [14]. While the parent drug itself has some
reactivity, these alcohol and aldehyde functional groups
are more reactive with proteins, forming adducts with the
proteins that can lead to lymphocyte-signaled apoptosis
[18]. Additionally, ROS produced by these functional groups
can subsequently damage proteins and DNA via oxidative
mechanisms and peroxidize lipids on the cell membrane [19].
These mechanisms can signal caspase-mediated apoptosis
and necrosis, respectively [20].
Polymorphisms in phase I DMEs are one of the better
characterized mechanisms that are responsible for idiosyn-
cratic reactions. The majority of the proteins that are clas-
sified as phase I DMEs are part of the cytochrome P450
oxidase (CYP450) family. The mechanism of metabolism
of CYP450 isoforms utilizes a heme to stabilize the inter-
mediate state along with adjacent residues [21]. Each of
the different isoforms of CYP450 present in hepatocytes is
capable of drug metabolism, but with different specificities
for the drugs. There are several isoforms of CYP450 that are
clinically relevant in idiosyncratic reactions. Among these
isoforms are CYP450 1A2 (CYP1A2), CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 [22,
23]. In addition to CYP450 enzymes, flavin monooxygenase
(FMO), alcohol dehydrogenase (ADH), aldehyde dehydro-
genase (ALDH), monoamine oxidase (MAO), and several
peroxidases are involved in phase I drug metabolism [14].
While all of these enzymes play roles in drugmetabolism, the
majority of incidences of ADRs are due to mutations in the
phase I DME genes which result in different polymorphisms
of the affected proteins that have altered activity of drug
metabolism [22, 24].
For example, CYP1A2 metabolizes many drugs, includ-
ing caffeine, clozapine, and fluvoxamine [22]. In addition,
CYP1A2 assists in the metabolism of bilirubin and several
hormones [25]. Two polymorphisms of CYP1A2 have been
found to affect metabolism. The CYP1A2∗1C polymorph
is found to decrease caffeine demethylation, while the ∗1F
polymorph is found to increase demethylation [22, 25].
The CYP2 family contains six enzymes with clinically
relevant polymorphisms. CYP2B6 metabolizes methadone,
cyclophosphamide, and nevirapine [26]. The most common
variant of thisDME is the ∗6 allele, which is present in 15–60%
of the population (variation is based on ethnicity and race)
[22, 27]. This allele and the ∗18 allele both show decreased
activity compared to thewild type 2B6 allele [22, 27]. CYP2C8
mediates the modification of several anticancer, antidiabetic,
and antimalarial drugs, including paclitaxel, troglitazone, and
amodiaquine [28]. In CYP2C8, the ∗2 form and ∗3 form both
impact paclitaxel clearance and turnover [29, 30]. CYP2C9
metabolizes an even broader range of drugs than CYP2C8,
and several polymorphisms are known to either reduce or
eliminate enzyme activity [22, 31]. CYP2C19 metabolizes
proton pump inhibitors and several antidepressants [22, 24].
All of the mutant forms, excluding ∗17, completely eliminate
the activity of the enzyme [32]. Ironically, the CYP2C19∗17
form increases the metabolism of omeprazole, while elimi-
nating the metabolism of the same drugs targeted by wild
type CYP2C19 [22, 32]. CYP2D6 metabolizes about 25% of
all known drugs, including tricyclic antidepressants (TCAs),
selective serotonin reuptake inhibitors (SSRIs), and tamox-
ifen [22, 33]. There are over one hundred different variants
of CYP2D6, and all of the clinically relevant variations show
decreased or lack of metabolism by CYP2D6 [33, 34]. Finally,
CYP2E1 metabolizes a variety of different drugs, including
antitubercular compounds, alcohol, and anesthetics [35, 36].
However, there are mutant genotypes of CYP2E1 that have
reduced metabolism of antitubercular drugs [22, 35, 37].
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Figure 1: Simplified mechanisms of drug metabolism in liver cells with potential pathways towards toxicity. Abbreviations are used as
follows: Na+-taurocholate cotransporting polypeptide (NTCP), organic cation transporter (OCT), organic anion transporting polypeptide
(OATP), bile salt export pump (BSEP), breast cancer resistance protein (BCRP), multidrug resistance protein (MDR), multidrug resistance-
associated protein (MRP), cytochrome P450 (CYP), flavin-containing monooxygenase (FMO), monoamine oxidase (MAO), UDP-
glucuronosyltransferases (UGT), sulfotransferase (SULT), glutathione S-transferase (GST), N-acetyl transferase (NAT), reactive oxygen
species (ROS), reactive nitrogen species (RNS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF𝜅B), nuclear factor
erythroid 2-related factor 2 (Nrf2), glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GPx), mitochondrial pore
transition (MPT), mitochondrial DNA (mtDNA), receptor-interacting serine/threonine protein kinase (RIPK), phosphoglycerate mutase
(PGAM), c-Jun N-terminal kinase (JNK), B-cell lymphoma 2 (Bcl2), antigen-presenting cell (APC), and Kupffer cell (KC) [12].
The CYP3A family of CYP450s are the most abundant
CYP450 isoforms, metabolizing close to sixty percent of
known drugs [38]. Of these, CYP3A4 metabolizes the most
drugs, though it has someoverlapping activitieswithCYP3A5
and CYP3A7 [22, 38]. All of the polymorphisms that affect
CYP3A4 and CYP3A5 activity either severely reduce or
eliminate the activity, while the only known polymorphisms
that affect CYP3A7 appear to increase the enzyme’s activity
[22, 38, 39]. Interestingly, most individuals do not carry a
functional CYP3A5, but when it is present, it is responsible
for one-third of the CYP3A activity [22, 38, 39].
The othermajor class of phase IDMEs that have polymor-
phisms that create susceptibility to ADRs is flavin monooxy-
genase (FMO). FMO catalyzes the oxygenation of many
compounds, particularly at nitrogen sites [40]. FMO3 is both
themost abundant of all the isoforms of FMOand the isoform
with themost known clinically relevant polymorphisms [40].
Loss of function of FMO3 results in trimethylaminuria, a con-
dition in which the body cannot break down trimethylamine,
leading the individual to develop a naturally “fish-smelling”
body odor and leaving the individualmore susceptible to liver
injury [41].
The susceptibility to IDILI due to dysfunction of phase I
drug metabolism stems heavily from race.The ∗1C variant of
CYP1A2 is more commonly found in Japanese populations,
while the ∗1F variant appears more frequently in Caucasians
[25]. 2B6 allelic expression is heavily tied to race, with the
∗
6 variant and ∗18 variants most commonly expressed in
New Guineans and Japanese, respectively [22, 42]. The ∗2
allele of CYP2C8 is more common in African populations,
while the ∗3 allele is more common in Caucasian populations
[43]. In CYP2C9, the ∗2 and ∗3 alleles are more common in
Caucasian populations, while themajority of othermutations
that reduce CYP2C9 activity are most commonly found in
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Table 1: Examples of drug metabolizing enzymes (DMEs) [17].
Classification Enzymes Overall reactions
Oxidative DMEs
(Phase I reactions)
Cytochrome P450 (CYP450) Carbon oxidationRH + O2 + NADPH + H+ → ROH + H2O + NADP+
Flavin-containing monooxygenase (FMO) N (or S) oxidationR-NH-R󸀠 + O2 + NADPH + H+ → R-NOH-R󸀠 + H2O + NADP+
Monoamine oxidase (MAO) Oxidative deaminationR-CH2NH2 + O2 + H2O→ R-CHO + H2O2 + NH3
Alcohol dehydrogenase Alcohol oxidationR-CH2OH + NAD+ → R-CHO + NADH + H+
Aldehyde dehydrogenase Aldehyde oxidationR-CHO + NAD(P)+ + H2O→ R-COOH + NAD(P)H + H+
Aldehyde oxidase Aldehyde oxidationR-CHO + O2 + H2O→ R-COOH + H2O2
Conjugative DMEs
(Phase II reactions)
UDP-glycosyltransferase (UGT) GlucuronidationR + UDP-glucuronic acid→ R-glucuronide + UDP
Glutathione S-transferase (GST)
Glutathione conjugation
R + GSH→ GS-R
R-X + GSH→ GS-R + HX
Sulfotransferase (SULT) SulfationR-XH + PAPS→ R-SO4 + phosphoadenosine + H+
N-Acetyltransferase (NAT)
Methylation
R-NH2 + CoA-S-COCH3 → R-NCOCH3 + CoA-SH
R-NHOH + CoA-S-COCH3 → R-NHOCOCH3 + CoA-SH
Xenobiotics (R), 𝛽-nicotinamide adenine dinucleotide phosphate (NADP), 𝛽-nicotinamide adenine dinucleotide (NAD), uridine 5󸀠-diphosphate (UDP),
glutathione (GSH), 3󸀠-phosphoadenosine 5󸀠-phosphosulfate (PAPS), and coenzyme A (CoA).
African populations [43, 44]. All of the clinically relevant
polymorphisms of CYP2C19 have varying frequency that
depends on race, with the ∗2 form being the most prevalent
of the polymorphisms that is found in Caucasians [22]. In
the CYP3A family, CYP3A4 does not have significant poly-
morphisms that are race dependent, but wild type CYP3A5
is more commonly found in African descent and less in
Caucasian descent [22, 45]. Additionally, some European
populations have a 20% incidence of a double null mutation
in FMO3 [22].
2.2. Phase II Drug Metabolizing Enzymes. Phase II DMEs
modify the drugs following phase I DME modification of
the parent drug. The action of phase II DMEs is to replace
the reactive aldehyde and alcohol functional groups with
less reactive and larger functional groups to direct the drug
towards clearance from the body. Phase II DMEs broadly
consist of uridine 5󸀠-diphospho-glucuronosyltransferases
(UGTs), sulfotransferases (SULTs), glutathione S-transferases
(GSTs), and N-acetyltransferases (NATs). All of the phase II
DMEs utilize cofactors to conjugate to reactive metabolites to
make ready for clearance. While the parent drug and drugs
metabolized by phase I and phase II DMEs can all be cleared,
clearance of phase II metabolized drugs provides the most
stable form of the drug and has a general tendency to lead
away from cholestasis and drug-induced liver injury (DILI)
[21, 22].
UGTs represent the most diverse class of phase II DMEs.
UGTs utilize uridine diphosphate glucuronic acid (UDP-
GA) as a cofactor for glucuronidation [46]. Glucuronides
are more stable than the reactive intermediates created by
phase I DMEs but are significantly less stable than drugs
metabolized by other phase II enzymes, particularly reactive
acyl glucuronides [46]. There are twenty-four known iso-
forms of UGT: nine belong to the UGT1 family and fifteen
belong to the UGT2 family [46]. Of all of the UGT isoforms,
UGT1A1 has the most clinically relevant polymorphisms,
owing to the fact that UGT1A1 metabolizes vast classes
of chemotherapeutics and bilirubin [47]. The UGT1A1∗6,
∗28, ∗33, and ∗34 mutations all result in decreased glu-
curonidation [48]. Having the UGT1A1∗28 variant results in
Gilbert’s syndrome and UGT1A1∗33 or UGT1A1∗34 results
in Crigler-Najjar syndrome, both of which are characterized
by hyperbilirubinemia [22, 48]. Certain polymorphisms in
UGT2B7 have potentially led to susceptibility to diclofenac
induced liver injury, though no other UGTs polymorphisms
have been found to lead to IDILI [49].
SULTs are found in the cytosol and perform a sulfa-
tion reaction using 3󸀠-phosphoadenosine-5󸀠-phosphosulfate
(PAPS) as a cofactor [50]. There are twelve known human
SULT enzymes, with SULT1 and SULT2 existing as the
most common SULT families in humans [51]. SULT1A1 and
SULT1A2 have the greatest number of clinically significant
polymorphisms of any of the SULTs [51, 52]. SULT1A1
sulfonates 4-hydroxy-tamoxifen, which actually increases the
efficacy of individuals carrying the wild type SULT1A1∗1
form [52]. This is decreased with individuals carrying the
SULT1A1∗2 form [52].
GSTs have several distinct polymorphisms that carry the
potential for idiosyncratic hepatotoxicity. GST conjugates
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glutathione to drugs for easy clearance [53]. This family of
phase II DMEs consists of seven subfamilies denoted by the
drugs that they metabolize [54]. The GSTT1 and GSTM1
double null phenotype has been found to lead to troglitazone
induced liver injury [55]. GSTP1 is a common metabolizing
enzyme of chemotherapeutics, and several polymorphisms
have been associated with increased risk of leukemia or
susceptibility to chemotherapeutic injury [22].
Humans contain two isoforms of NAT: NAT1 and NAT2
[56]. Both isoforms of NAT function to acetylate parent
drugs and reactive metabolites using acetyl coenzyme A
(CoA) as a cofactor [56]. Substrates for NAT1 include p-
aminobenzoic acid (PABA) and p-aminosalicylic acid (PAS),
while substrates for NAT2 include isoniazid, hydralazine, and
sulfonamides [22].While there are approximately twenty-five
known polymorphisms of NAT, mutations in NAT2 appear
to have a more dramatic effect on acetylation reactions [22].
Slow acetylation has been observed in the NAT1∗14 and
∗17 phenotypes, but isoniazid toxicity has been observed in
people with null phenotypes of NAT2, and increased toxicity
potential towards amonafide was observed in higher NAT2
activity [22].
Incidents of polymorphisms of phase II DMEs have been
found to be race dependent. Slow acetylation from NAT2 is
found to occur in about half of Caucasians, but only 10% of
Japanese [57, 58]. Incidences of polymorphisms in SULT2A1
are significantly higher in people of African descent, but
these polymorphisms have not been found to have clinical
relevance [45]. Additionally, SULT1A1 polymorphisms that
affect activity are found to be represented in different ethnic
groups at different frequencies [52]. UGT1A1∗6 is common
in people of Asian descent, while 1/3 of Caucasians and a
significant portion of people of African descent are carriers
of the UGT1A1∗28 gene [48, 59]. Additionally, the wild type
variant of GSTP1 is present in 60–90% of the population; a
statistic that is race dependent [53].
2.3. Antioxidant Enzymes. Antioxidant enzymes play a key
role in the prevention of cellular injury by reactive ROS
(Figure 2). ROS that exist inside the cell include superoxide
anion (O2
∙−), hydrogen peroxide (H2O2), and hydroxyl radi-
cal (OH∙) among others [60, 61]. A cell’s defense to oxidative
injury includes the abundance of glutathione (GSH), as
well as antioxidant enzymes superoxide dismutase (SOD),
catalase (CAT), glutathione peroxidase (GPx), peroxiredoxin
(Prx), and thioredoxin (Trx) (Figure 2) [62, 63]. GSH, as a
relatively small peptide, can rapidly react with ROS to protect
the cell from oxidative injury. However, once approximately
90% of the GSH is depleted within a cell, its susceptibility to
oxidative death increases significantly [64, 65].Thus, the roles
of these enzymes in the reduction of ROS are critical to cell
survival of oxidative stress.
The antioxidant enzymes within the hepatocytes will
generally exist in the mitochondria or the cytosol. How-
ever, many of the effects of ROS and the malfunctions
of antioxidant enzymes can be observed in mitochondrial
behavior. During a hepatotoxic event, mitochondria undergo
an event known as mitochondria permeability transition
(MPT) [15]. In MPT, stress causes mitochondria pores to
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Figure 2: Mechanisms of mediating ROS within the liver. Abbre-
viations are used as follows: superoxide dismutase (SOD), catalase
(CAT), peroxiredoxin (Prx), thioredoxin (Trx), thioredoxin reduc-
tase (TrxR), glutathione peroxidase (GPx), glutathione (GSH), and
glutathione disulfide (GSSG).
swell, allowing passage of solutes of up to 1500Da, including
ROS, Ca2+ efflux, and the influx of potentially reactive
metabolites [15]. Subsequent events of this include decreased
levels oxidative phosphorylation, mitochondrial depolariza-
tion, swelling, and subsequent death of the cell by either
apoptosis via cytochrome c release or necrosis via ATP
depletion [66–68]. Both mechanisms of cell death have been
observed to be caused by various hepatotoxicants. Though
necrosis is generally found in more cases of DILI, apoptosis
is heavily tied with the mechanisms related to immunemedi-
ated hepatotoxicity as the role of cytokines in inflammation
can exacerbate much of the oxidative stress occurring within
the cell [69, 70]. By mitigating ROS, antioxidant enzymes can
decrease the frequency of this occurrence.
The mechanisms of these antioxidant enzymes serve to
either convert more reactive ROS to H2O2 or convert all ROS
to H2O. The enzymatic antioxidants in the body all contain
a metallic core to stabilize and catalyze the conversion of
ROS to H2O. In the case of SOD, the metals at the core
can be copper and zinc or manganese for humans, where
CuSOD and ZnSOD are in the cytosol or are extracellular,
and MnSOD is in the mitochondria [71]. SOD generally
converts superoxide anion and water to O2 and hydrogen
peroxide [71]. Humans contain three isoforms of SOD: SOD1,
SOD2, and SOD3. SOD1 is a dimer located in the cytosol,
SOD2 is a tetramer located in the mitochondria, and SOD3
is an extracellular tetramer [71]. SOD1 and SOD2 are the
more clinically relevant isoforms in regard to idiosyncratic
hepatotoxicity since SOD3 is extracellular and affects all
organs. Specifically, organisms homozygous for a deletion
in SOD2 die due to oxidative damage of the liver, while
those heterozygous for functional SOD2 are still at risk for
injury [62]. Additionally, people who are heterozygous for
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either SOD1 or SOD2 deletions are at increased risk for
hepatocellular carcinoma [62].
GPx is another enzyme that plays an important role in
mitigating oxidative stress, but if deleted may also make an
individual more susceptible to hepatotoxicity. GPx serves
to catalyze conversion of hydrogen peroxide to water by
creating a sulfide bond between two GSHmolecules, creating
glutathione disulfide (GSSG) [72]. This enzyme works in
conjunction with glutathione reductase (GR), which reduces
GSSG to GSH via oxidation of NADPH [72, 73]. GPx uses a
selenium core to assist in the catalysis.There are eight known
isoforms of GPx (denoted GPx1–8), but the two isoforms
most involved in hepatoprotection are GPx1 and GPx4 [62,
73]. GPx1 exists in the cytoplasm and mitochondria, while
GPx4 is uniformly distributed throughout the cell [62].
Besides converting peroxides to water, GPx also functions
in removing peroxides from lipids. Most deletions in GPx
have a greater impact on lipid peroxidation than in standard
DILI, and fatty liver disease is present in individuals with
less functional GPx. Mutations in GPx1 have been shown
to potentially induce cholestasis and toxicity due to drug
accumulation in the bile [62]. GPx4 mutations generally
affect bone tissue more significantly, but there are impacts to
liver tissue as well [62].
Among other antioxidant enzymes of note are CAT,
Prx, and Trx. CAT is a heme-based tetramer protein that
catalyzes the conversion of hydrogen peroxide towaterwithin
the peroxisome of the cell [74]. While CAT does play an
important role in reducing ROS, deficiencies in CAT do
not have correlation with increased risk of idiosyncratic
hepatotoxicity, nor is it considered to put an individual at risk
for other diseases [62].
Unlike the aforementioned enzymes, Prx, Trx, and thiore-
doxin reductase (TrxR) do not catalyze the reduction of ROS
using metals. Instead, the mechanism relies on interactions
with sulfide bonds in cysteine residues on Prx [75]. Prx
and Trx work in conjunction with each other, where Prx
converts hydrogen peroxide to water. Then, Trx reduces the
oxidized form of Prx, and Trx is itself reduced by thioredoxin
reductase (TrxR), coupling the oxidation of NADPH to
NADP [75].There are six isoforms of Prx that can be localized
to the mitochondria, cytosol, peroxisome, or extracellular
space. Deletions in Prx isoforms do not seem to affect
hepatotoxicity, though circulating erythrocytes are affected
by mutations in Prx. Deletions in any of the genes that code
for Trx are lethal, and studies have shown that mice with
elevated levels of Trx live longer. Additionally, a recent study
has suggested that deletions in genes coding for TrxR1 show
to put organisms at greater risk of DILI [76].
The most prevalent cause for susceptibility to ADRs
due to problems with antioxidant enzymes is age. The
suspected reason for this age related susceptibility is the
general decreased ability of cells to deal with oxidative stress.
The mitochondria itself is more likely to break down and
functions with antioxidant enzymes in the mitochondria,
including SOD2 and GPx1 [62]. Additionally, evidence sug-
gests that higher levels of antioxidant enzymes can slow down
the body from physiologically aging. This decreased level
of antioxidant activity upon aging is a reason suspected for
why older patients are at greater risk for experiencing ADRs.
In addition to age, postmenopausal females are at a higher
risk for DILI than premenopausal females and males that are
older than fifty [62].The hypothesis behind this is that higher
levels of muscle tone (particularly lean muscle) promote
antioxidant activity. While muscle does degrade with age,
women are more susceptible to this injury due to lower initial
muscle tone.
2.4. Hepatic Transporters. Drug transporter proteins are cru-
cial for clearance of reactive metabolites in the liver, kidney,
intestine, and brain (Figure 3) [77]. Hepatic transporters can
be classified by mechanism of action and by location on the
hepatocyte cell membrane. Transport of drugs into or out of
the cell can be governed by the ATP-binding cassette (ABC)
transporter family of proteins or the solute carrier (SLC)
family of proteins [13]. Generally, SLCproteins are considered
to be influx transporters [78], moving drugs from the plasma
into the cell. ABC transporters are efflux transporters,moving
metabolized drugs from within the cell into the bile [79–81].
The transporter families of greatest clinical relevance
within the hepatocyte include organic anion transporting
polypeptides (OATPs), organic cation transporters (OCTs),
multidrug resistance proteins (MDRs), breast cancer resis-
tance protein (BCRP), the bile salt export pump (BSEP),
and multidrug resistance-associated proteins (MRPs) [82,
83]. The OCTs and the OATPs are part of the SLC class
of transporter proteins, relying on coupled cation/anion
transport, as a mechanism of facilitated diffusion down a
concentration gradient [82]. Generally, these proteins are
characterized as having twelve transmembrane hydrophobic
domains that stabilize its structure within the cell membrane.
Both classes of proteins function to carry drugs into the cell
[14]. While OCT1 is an important liver influx transporter, it
is also found within the intestine, so idiosyncratic reactions
can occur in both organs [13, 24]. The OATP1B subfamily
of proteins (specifically OATP1B1 and OATP1B3) is strictly
found in the liver, making it an ideal protein to study
for strict hepatotoxicity. Additionally, the Na+-taurocholate
transporting peptide (NTCP) is another SLC protein that
plays a role in influx transport that is localized to the liver
[77, 84].Of all the influx transporters, OATP1B andNTCP are
found to have the greatest effect on drug transport [77, 84].
Idiosyncratic reactions are not significantly associated
with the SLC transporters. However, OCT1 and OATP1B1 are
both found to have clinically relevant polymorphisms. Peo-
ple with defective OCT1 have trouble transporting cationic
substrates of metformin [85], while mutations in OATP1B1
have been shown to cause increases in the accumulation
of sulfoconjugated troglitazone [13, 24, 86]. Additionally,
OATP1B1 mutations have been implicated with increased
susceptibility to hyperbilirubinemia [87].
MDRs, BCRP, BSEP, and MRPs are all efflux transporters
of the ABC family with clinical relevance in hepatotoxicity.
MDR1 (also known as P-glycoprotein) transports a significant
amount of xenobiotics and biological compounds into the
bile [88–90]. While MDR1 can be found in many tissues,
it also has many substrates, making it an important efflux
transporter [13]. Additionally, MDR3 is strictly found in
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Figure 3: Transporter mechanisms on the cell membranes of hepatocytes. Proteins that are labeled yellow have known clinically relevant
polymorphisms, while green labeled proteins do not have known clinically relevant polymorphisms. Abbreviations are used as follows:
organic cation transporter (OCT), organic anion transporter (OAT), organic anion transporting polypeptide (OATP), Na+-taurocholate
cotransporting polypeptide (NTCP), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), multidrug resistance protein
(MDR), multidrug resistance-associated protein (MRP), organic solute transporter (OST), and multidrug and toxin extrusion protein
(MATE) [13].
hepatocytes, working with ATP8A1 to regulate the transport
of phospholipids across the cell membrane [91]. BCRP plays
roles in both porphyrin transport and secretion of vitamins
in breast milk [92]. While this protein is also found in many
cell types, porphyrin release is the most common function
found in hepatocytes [92, 93]. BSEP is a protein localized to
hepatocytes that functions in the transport of bile salts into
the bile canaliculi [94]. As a result, BSEP is an important
regulatory in bile flow. Finally, MRP2, 3, 4, and 6 individually
act as efflux transporters of hepatocytes, but only MRP2
conducts xenobiotics into the bile [77].
While mutations can occur in both families of trans-
porters, the mutations affecting ABC transporters are con-
sidered to be more clinically relevant. Mutations in ABC
transporters mean that metabolized drugs cannot leave the
hepatocytes, leading to impaired canalicular bile flow. This
generally manifests in the form of cholestasis and fatty liver
disease [94, 95]. MDR1, BSEP, BCRP, and MRP2 all have
polymorphisms that have been associated with idiosyncratic
ADRs. Mutations in MDR1 have been implicated in efflux
transport of verapamil [89]. Altered expression of BCRP has
affected patients taking anticancer drugs or weight loss drugs,
including gefitinib, irinotecan, topotecan, and diflomotecan
[24, 96]. Mutations in BSEP have been implicated in early
onset hepatocellular carcinoma, along with an increase in
susceptibility to cholestatic injury from carbocyclic com-
pounds with aromatic rings [97]. Generally, inhibition of
BSEP has been correlated with the incidence of cholestatic
liver disease [98, 99]. MRP2 mutations can also result in
increased susceptibility to hyperbilirubinemia, as well as
increased susceptibility to injury due to methotrexate [24,
100] and pravastatin [24, 101].
Age and race both play a significant role in the risk for
ADRs from variations in the expression of transporter genes.
Increasing age can reduce the expression of several efflux
transporter proteins. In particular, mRNA levels of MDR1
are decreased in elderly patients. The expression of MDR1
is generally heterogeneous, and this expression becomes
even more pronounced with age [102, 103]. Additionally,
OATP1B1 has about fourteen known mutations that have
been found to exist within individual populations of peo-
ple from either European, African, or Asian descent [13].
Frequent polymorphisms of OATP1B1 found in Caucasians
include OATP1B1∗1b and OATP1B1∗4, but mutations result-
ing in OATP1B1p.L193R show decreased transport compared
to the other forms of OATP1B1 [13]. Individuals with the
OATP1B1∗15 haplotype, which is found in Japanese people,
have general reduced transport activity of OATP1B1 [13,
92]. MRP2 mutations found in Korean people have also
been found to increase the susceptibility to IDILI by herbal
medicines [24].
2.5. Immunological Mechanisms. Immunological mecha-
nisms towards drug reactions represent a diverse set
of idiosyncratic reactions. Livers have a resident set of
macrophages called Kupffer Cells (KCs), which initiate
inflammation in the liver after drug exposure [61, 104].
Additionally, the liver is permeated with small populations
of other lymphocytes, including other macrophages, T cells,
B cells, and natural killer (NK) cells [3, 16, 70]. Owing to
the liver’s role in detoxification, these cells are necessary for
developing foreign body responses.
During drug metabolism, damaged proteins may be
expressed on the surface of hepatocytes. Lymphocytes can
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Figure 4: Simplified mechanisms of inflammation signaling caused by adverse drug reactions (ADRs) in the liver. Abbreviations are used
as follows: toll-like receptor (TLR), major histocompatibility complex (MHC), T cell receptor (TCR), drug metabolizing enzymes (DMEs),
antigen-presenting cell (APC), cytotoxic T lymphocyte (TC cell), and helper T lymphocyte (TH cell).
initiate and regulate inflammation by recognizing drugs and
hepatocytes that have metabolized drugs as foreign bodies,
either via recognizing the drug in solution or by recognizing
damaged proteins on the surface of hepatocytes [61, 105]
(Figure 4). During long-term drug exposure, a healthy liver
may experience some inflammation that subsides with time.
However, ADRs can manifest with significant inflammation
in the liver, leading to drug-induced autoimmune hepatitis
(DIAIH) or acute liver toxicity [70, 106]. Generally, this
mechanism has been considered to be the “failure-to-adapt”
model [10].This model assumes that injury occurs after long-
term exposure to drugs and is regulated by the levels of
cytokines present during the adverse reaction.
IDILI associated with the failure-to-adaptmodel assumes
the dysfunction in the expression of cytokines. In stan-
dard inflammation, a subset of macrophages called M1
macrophages (or, in the case of the liver, KCs) phagocytoses
antigens derived from dead or dying cells called damaged-
associate molecular patterns (DAMPs) before presentation
on major histocompatibility complex (MHC) [107]. In addi-
tion to KCs, circulating macrophages, dendritic cells (DCs)
neutrophils, and subsets of B and T cells with innate activity
can respond to the presence of antigen [107]. Macrophages
can present on MHC I or MHC II, which will either lead
to the initiation of a cellular immune response by the CD8+
T cytotoxic (TC) cells, or a humoral immune response by
T helper (TH) cells [107]. TH1 cells, a variant of T helper
cells, also help activate TC cells in a delayed hypersensitivity
response via secretion of interferon gamma (IFN-𝛾) and
tumor necrosis factor alpha (TNF-𝛼) [108]. Another subset,
TH17 cells, promotes inflammation by secreting interleukin
17 (IL-17) cytokines [109]. In a healthy individual, this
inflammation subsides via activity of T regulatory (Treg) cells,
another TH cell subset that secretes regulatory cytokines,
including IL-10 and transforming growth factor beta (TGF-
𝛽) [108].
The deregulation of cytokines is a potential mechanism
for IDILI. In inflammation-based liver injury, the excess of
proinflammatory cytokines and the reduction of regulatory
cytokines cause general cell death within the liver rather than
targeting the liver cells that express damagedmotifs [110, 111].
Inducing expression of inflammatory cytokines IL-1𝛼 and
the use of anti-TNF-𝛼 antibodies increase the susceptibility
to DILI [108]. IL-1𝛼 is proinflammatory, whereas TNF-𝛼
is regulatory, so the absence of antibodies against TNF-𝛼
actually increases the chance for inflammation. In addition,
IFN-𝛾 and IL-1𝛼 both appear to induce inflammation during
acetaminophen-induced liver injury [104, 108]. It has also
been found that mutations in anti-inflammatory cytokines
IL-4 and IL-10 can increase the risk of diclofenac induced
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liver injury in humans [112, 113]. While individual muta-
tions can increase susceptibility to injury, double mutations
provide an even greater risk to IDILI [11, 114]. Additionally,
the source of cytokine deregulation is debated, as mutations
can either affect master transcriptional regulators [115] or
the actual cytokine [116].This inflammation deregulation can
be found in nonsteroidal anti-inflammatory drugs (NSAIDs)
[116, 117] and antibiotics [69, 118].
While KCs are the predominant lymphocyte in the
liver, there is a belief that deregulation often stems from
defects in TH17 cells, leading to autoimmune responses [109].
TH17 deregulation has been implicated in other autoimmune
diseases, including juvenile diabetes, Crohn’s disease, mul-
tiple sclerosis, and rheumatoid arthritis [109]. It has been
found that levels of proinflammatory cytokines IL-17 and
IL-22 are elevated in the presence of penicillamine [114,
119]. In addition, the level of circulating TH17 cells is also
increased, corresponding with the increases in IL-17 and IL-
22 [114]. TH17 cell production is induced by IL-6 secretion
of macrophages, which is pleiotropic [109]. Thus, there is
significant interplay between the types of cells in the immune
system and the potential for idiosyncratic drug reactions.
Another potential mechanism of IDILI is that human
leukocyte antigen (HLA) haplotypewill affect the recognition
of the immune system of cells presenting damaged motifs.
HLA codes for the MHC in humans. In adults, the HLA-A,
HLA-B, and HLA-C genes govern the structure of MHC I,
while HLA-DP, HLA-DQ, and HLA-DR govern the structure
ofMHC II [120].While there is one gene for each of theMHC
I coding regions, there are eight genes responsible for MHC
II [120]. Individually, this leaves 1000–2000 different allotypes
for each of the HLA-A, -B, and -C genes and 2–860 allotypes
for each of the eight -D genes [120]. This yields a total of 1.7
billion haplotypes for MHC I and 1015 haplotypes for MHC
II.
Generally, HLA polymorphisms associated with
increased susceptibility to IDILI are found on the MHC
II locus. This means that signaling from CD4+ TH cells is
directly affected, as these cells have direct interaction with
MHC II. Additionally, because of the significant role of
TH cells in regulatory signaling, there are effects seen in
the behavior of other lymphocytes, including TC cells and
KCs. The majority of known polymorphisms associated
with HLA are found on HLA-DRB1, though there is a
significant presence of polymorphisms affecting HLA-DQ
as well [24, 121, 122]. While most of these polymorphisms
are associated with increased disposition towards cholestatic
liver injury, there are at least three known polymorphisms
associated with increased toxicity towards amoxicillin
[121, 122]. There are a set of mutations in HLA-DQ that
predispose towards lumiracoxib-related liver injury [123].
Additionally, HLA-B has at least one known polymorphism
to increase susceptibility to flucloxacillin [124, 125], and
others that are more predisposed towards antiepileptic
drugs [111]. Owing to the fact that HLA-DQ and HLA-DR
polymorphisms code for polymorphisms in MHC II, it is
possible that many of the deregulated cytokines are as a result
of indirect effects fromMHC II with altered functionality.
IADR predisposition via possible immune-based mech-
anisms can be found as a function of gender, age, race,
and current immune state. Often, those that are immune
compromised, such as people with autoimmune illnesses
affecting inflammation will be more at risk for IDILI due to
the dysfunction of cells that govern both mechanisms. It has
been found that women with breast cancer with the HLA-
DQA1∗02:01 are more at risk to develop an IADR to certain
breast cancer therapeutics than women with breast cancer
with a different HLA haplotype [126]. Japanese are more at
risk for HLA-mediated ticlopidine IDILI [127]. Additionally,
age plays a significant role in cytokine-mediated ADRs,
as DNA is more susceptible to mutation and autoimmune
diseases inducing inflammation become overly prevalent
[106, 109, 114].
3. Assays Detecting Susceptibility for
Idiosyncratic Reactions
In clinical trials and in vivo tests, the assessment of ADR
potential is developed by use of measuring biomarkers
alanine transferase (ALT), aspartate transaminase (AST), and
bilirubin [128, 129]. ALT and AST are general biomarkers
for protein catabolism, while bilirubin is an indicator of
cholestasis and bile flow. While other biomarkers have been
developed to assess liver behavior, the combination of ele-
vated ALT, AST, and bilirubin levels is the general indicator
for potential of liver injury. The rule for assessing if DILI will
occur was developed by Hy Zimmerman: it states that liver
injury is likely to occur when an organism is exposed to drugs
exhibits five times the upper limit of normal (ULN) for ALT
activity, 3 × ULN for AST, and 2 × ULN for total bilirubin
(TBL) found in serum [130].While positively identifying that
the markers for Hy’s Law correlate with increased risk for
DILI, the absence of these markers does not rule out liver
injury [128]. Additionally, it is possible that the combination
of factors may not even result in injury to the liver. Thus,
reliance on other markers to predict and detect injury is
necessary for proper drug development.
Developing assays for detecting the potential for IDILI
relies on screening individual events. While conventional
assays may characterize drug metabolite formation and the
general potential for ADRs; very little emphasis has been put
on detecting the potential for IADRs. Assays for detecting
inflammation in vivo and CYP450 activity assays in vitro
have been developed for clinical and industrial use, but
very few assays have been developed to predict ADRs in
individuals with polymorphisms in transporters, phase II
DMEs, or antioxidant enzymes. Here, we will describe assays
that can be used for detecting IADRs, with emphasis on in
vitro systems, preferably ones that can be used for high-
throughput screening (HCS) of potentially toxic compounds
(see Table 2).
3.1. CYP450 Activity Assays. Measuring individual enzyme
activity can provide information on potential mutation
of DMEs indirectly. Coumarin-based substrates have been
used to determine the activity of various CYP450 isoforms
10 BioMed Research International
Table 2: Assays used for determining IDILI potential.
Mechanisms Proteins Relevant assays
Phase I DMEs CYP450
Coumarin metabolism
Fluorescein (CYP2C9)
Human liver microsomes (HLMs)
High pressure liquid chromatography (HPLC)/Mass
spectrometry (MS)
Phase II DMEs
UGT Coumarin metabolism
GST (GSTT1 and GSTM1) CDNB, NBC, DCNB, EPNP, DCM, PBOGSTT1/GSTM1 single and double knockouts
UGT/GST/NAT/SULT Covalent binding level (CBL)HPLC/MS
Antioxidant
enzymes GPx1/SOD2
Monochlorobimane (mBCl)
Oxygen consumption rate (OCR)
Fluorescein
Tetramethyl rhodamine (TMRM)
Cytochrome c release
SOD2+/− mice
Transporters
BSEP Vesicular transport assay (VTA)ATPase assay
MRP2 Fluorescein
MDR1/MRP2 Flow cytometry
OCT OCT1 and OCT2 knockouts
BSEP/BCRP/MDR/MRP/OATP/OCT/NTCP HPLC/MSDrug uptake assays
Inflammation
TNFR1/IFN-𝛾/TLR9/IL-1/IL-4/IL-6/IL-10/IL-13
LPS-induced inflammation
Lymphocyte transformation test (LTT)
Cytokine production
Cytokine knockouts
CD69 Flow cytometry
HLA MHC I/MHC II Flow cytometry
Cytochrome P450 (CYP450), uridine 5󸀠-diphosphate (UDP) glycosyltransferase (UGT), glutathione S-transferase (GST), N-acetyl transferase (NAT),
sulfotransferase (SULT), glutathione peroxidase (GPx), superoxide dismutase (SOD), 1-chloro-2,4-dinitrobenzene (CDNB), p-nitrobenzyl chloride (NBC), 1,2-
chloro-4-nitrobenzene (DCNB), 2-epoxy-3-(p-nitrophenoxy)propane (EPNP), dichloromethane (DCM), trans-4-phenyl-3-buten-2-one (PBO), lipopolysac-
charide (LPS), tumor necrosis factor R1 (TNFR1), interferon gamma (IFN-𝛾), toll-like receptor (TLR), interleukin (IL), cluster of differentiation (CD), major
histocompatibility complex class I (MHC I), and class II (MHC II).
(Figure 5). Each isoform can metabolize a different substrate,
though there could be some substrate overlap [23, 131]. For
example, 7-ethyloxymethyloxy-3-cyanocoumarin (EOMCC)
can be metabolized via CYP1A2, CYP2D6, or CYP2E1, along
with other CYP450 isoforms. The listed reactions occur
via hydroxylation of the ethoxy or methoxy oxygen on the
fluorescent compound. Additionally, all of the metabolites
excite at 355 nm, but the HFC emits at a different wave-
length than the metabolites formed by CYP1A2 and CYP3A4
metabolism, allowing for two CYP activities to be measured
in one well.The drawback to these substrates is that if the cell
line is capable of significant phase II metabolism, inhibitors
need to be added to the solution to properly assess CYP450
activity.
While CYP2C activity might not be modeled by the
coumarin fluorogenic substrates, activity can still be mea-
sured using conversion of dibenzylfluorescein (DBF) to
fluorescein by CYP2C8 and CYP2C9 [23]. DBF requires
low concentrations for drug metabolism and generally gives
a strong fluorescent signal when CYP2C9 metabolism is
present. Additionally, CYP3A4 activity may be quantified
using Luciferin-based luminescent reagents [132].
In addition to standard fluorogenic substrate assays, drug
metabolites can be pooled from media and quantified using
high performance liquid chromatography (HPLC) and mass
spectrometry (MS) [133–135]. The advantage of this is that
endpoint activity can be quantified along with cell viability to
determine if a therapeutic is potentially toxic to individuals or
whole populations. However, this system is generally better
suited for endpoint therapeutic studies, and there is great
financial cost associated with performing HPLC and MS to
quantify CYP450 activity.
In addition to recombinant individual DMEs used,
human liver microsomes (HLMs), the centrifuged product of
lysed liver tissues, are commonly used to measure a desired
activity. Generally, HLMs contain a large concentration of
CYP450s and some phase II DMEs such as UGTs, and HLMs
can be used to measure the expression levels of CYP450s in
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Figure 5: Metabolism of coumarin by CYP450 isoforms. Abbreviations are used as follows: 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-
7-methoxy-4-methylcoumarin (AMMC), and 3-[2-(N,N-diethylamino)ethyl]-7-hydroxy-4-methylcoumarin (AHMC).
the liver tissues from which they were isolated. Walsky and
Obach usedHLMs tomonitormetabolic activity over a range
of compounds that can be metabolized by CYP450s [131].
3.2. Phase II DME Assays. Specific protein assays that are
relevant to IADRs are targeted towards measuring UGT
and GST activity. One way to measure UGT activity is the
fluorescent substrate 4-methylumbelliferone (4-MU), which
is a coumarin derivative that undergoes glucuronidation [136,
137]. UGT’s role in clearance of steroids makes steroidal
compounds good substrates to assay for UGT specific activity
aswell [82]. In the case ofGST, levels and activity can be quan-
tified via the removal of chlorine from substrate 1-chloro-
2,4-dinitrobenzene (CDNB) [138]. While CDNB can be used
as a substrate for total GST activity, p-nitrobenzyl chloride
(NBC), 1,2-chloro-4-nitrobenzene (DCNB), and trans-4-
phenyl-3-buten-2-one (PBO) can be used to detect GSTM
activity, and 1,2-epoxy-3-(p-nitrophenoxy)propane (EPNP)
and dichloromethane (DCM) can be used as substrates for
GSTTs [139, 140].
A functional assay can be used to determine idiosyncratic
reactions in phase II DMEs in determining the covalent
binding level (CBL) [55]. Because drugs that have been only
metabolized by phase I DMEs are more reactive than the
parent drug or drugs that have been successfully conjugated
with bulkier functional groups, computation of CBL can be
used to assess either reactive metabolite formation potential
or the rate at which the metabolite is not being cleared from
the hepatocyte.
Glucuronidation can be quantified using methods such
as HPLC and MS [141]. Surendradoss et al. used HPLC
and MS to quantify valproyl 1-O-acyl-glucuronide (VPA-
G), the phase II metabolized drug of valproic acid [142,
143]. Additionally, diclofenac conjugated to GSH has been
measured via HPLC to assay for GST activity [140]. The
drawback to using these technologies is that metabolites can
only be quantified in relative terms without giving exact
values as to the forms of drug present in a solution. This
leadsmetabolite analysis to be performed only for diagnosing
an idiosyncratic event rather than determining its severity.
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For reactive metabolite counts, GSH trapping can be used to
quantify the level of oxidative metabolites before being run
throughHPLC andMS [144]. Additionally, adduct formation
of proteins can also be measured using LC-MS, providing
insight towards the mechanism of injury [117, 145].
In in vivo models, the GSTT1 and GSTM1 single-null
and double null mutation has been thoroughly studied in
regard to troglitazone induced ADRs in mice [35, 55]. These
particular models are beneficial because there has been
shown an additive effect towards generating IDILI with these
responses.
3.3. Mitochondrial Activity Assays. One of the difficulties
associated with determining idiosyncratic reactions with
antioxidant enzymes is that very few of the assays can target
specific protein functions, and they are designed for general
ADRs as mitochondrial dysfunction is often a symptom
(rather than the cause) of hepatotoxicity. Due to the fact
that ADRs blamed on antioxidant toxicity are associated
with proteins found in the mitochondrion, it is the primary
indicator for liver functionality tests. Certain assays, such
as the cupric ion reducing antioxidant capacity (CUPRAC)
assay [146] or the MitoTracker dye [147], can rely on calcu-
lating general antioxidant capacity within a cell, or confocal
microscopy to examine individual mitochondrial behavior.
However, general assays are more geared towards calculat-
ing antioxidant potential associated with smaller molecules,
including ascorbic acid and tocopherol. Additionally, 2󸀠,7󸀠-
dichlorodihydrofluorescein (H2DCF) can be used tomeasure
general oxidative stress [148, 149]. However, this too is not
specific for idiosyncratic mechanisms.
Mitochondrial dysfunction is a considerable target for
drug toxicity screens. For general mitochondrial toxic-
ity assays, measuring mitochondrial membrane potential
(MMP) via fluorescent compound tetramethyl rhodamine
(TMRM) can be used to quantify apoptosis as MMP depo-
larization is symptomatic of the issue [148]. Besides MMP,
cytochrome c release and variation in the oxygen con-
sumption rate (OCR), which is the turnover of O2 during
metabolism, may be symptomatic of mitotoxicity [150–153].
MitoTox has been used as a phosphorescent probe for
the general measurement of OCR [151–153]. Additionally,
Liang et al. managed to purify mitochondria and assay for
GPx activity, though the method is not durable for high-
throughput applications [138].
Owing to the role of mitochondria in reduction of
ROS, antioxidant GSH is an adequate substrate for assessing
mitotoxicity. One commonly used compound, monochloro-
bimane (mBCl), is fluorogenic in the presence of glutathione
[154]. This substrate reacts with thiol based compounds, so
fluorescence can correlate well with substrate depletion [154,
155]. While GSH acts as a general indicator for oxidative
stress, this can be sufficient enough to indicate dysfunction
with antioxidant enzymes, or even the general presence of an
IADR. Other protocols are able to discriminate between GSH
andGSSG based on the GS-GPx oxidation-reductionmecha-
nism [101, 156].The protocol however is reagent intensive and
is not compatible with high-throughput drug screening.
One of the more common mutations studied is a het-
erozygous SOD2 mouse [117, 154]. A homozygous knockout
for SOD2 is lethal to the organism due to SOD2 being the
major enzyme responsible for removal of oxidant sources
in the cell. Yet, a heterozygous expression of normal SOD2
results in a viable mouse with a decreased ability to reduce
intracellular ROS. The SOD2 heterozygous mouse has been
used to study cardiac function, aging, and drug metabolism.
While significant studies have been done to show the poten-
tial for gene knockouts in SOD2, very few studies have
been done for GPx1, which has also been shown to have
polymorphisms with clinical relevance.
3.4. Transporter Assays. In the assessment of transporter
activity, BSEP is commonly assayed because its dysfunction is
correlatedwith cholestasis. CommonBSEP assays include the
vesicular transport assay (VTA) and the ATPase assay [94],
both of which rely on the presence of ATP as a to drive the
protein function and hence the assay. Because both assays
rely on ATP, this makes VTA and the ATPase assay also
suitable for ABC transporter proteins. In addition to VTP
and ATPase, taurocholate may be used for measuring BSEP
transport [157].
Drug uptake and release assays are also available for
other compounds and transporter proteins [158]. Owing
to the common regulation of MDR1 and CYP3A4 via the
pregnane X receptor (PXR), there is significant overlap in
compounds that can be used to assay transporter activity
[77, 86, 88]. Examples of this are rifampicin and verapamil as
inducers and inhibitors of MDR1 activity, respectively [77].
In the influx transporter system, OATP1B1 and OATP1B3
have broad substrate specificity that can be used to mea-
sure activity, including rifampicin [159, 160], taurocholate
[161], and pitavastatin [82]. For other transporters, MRP2
is inhibited via a fluorescent compound, 5(6)-carboxy-2󸀠,7󸀠-
dichlorofluorescein (CDCF) [82, 157, 162]. Additionally, OCT
knockouts have been generated in mice, including double
knockouts of OCT1 and OCT2 [77].
Flow cytometry can be used to diagnose potential for
idiosyncratic reactions via transporter and immune medi-
ated mechanisms. The principle of flow cytometry utilizes
cell counting and cell sorting based on immunofluorescent
labeling of cell surface markers. Transporter proteins and
lymphocytes are ideal detection markers for flow cytometry
because they exist on the cell surface and are stainable
with fluorescent antibodies. Saab et al. used microvolume
flow cytometry to assess the behavior of MDR1 and MRP2
as associated risks with IDILI [89]. By staining for efflux
transporters, they were able to detect toxicity potential due
to synergistic effects of several known idiosyncratic drugs
with known effects to induce inflammation. Perez et al.
used flow cytometry to quantify the behavior of several
efflux transporters by examining ROS production due to
mitochondrial deregulation [90].
3.5. Inflammation Assays and Immune System Dysfunction.
Cytokine analysis is an effective tool for quantifying ADRs
for long-termdrug administration. In addition, cytokines can
BioMed Research International 13
be readily quantified in both serum and media. A common
practice is to administer agonists that induce inflamma-
tion, such as lipopolysaccharide, (LPS) to activate toll-like
receptor- (TLR-) mediated inflammation and apoptosis [163,
164]. Caspase 3/7 activity assays are a common assay used
to measure inflammation-mediated apoptosis [19]. Because
of the diversity of symptoms associated with IDILI, time
dependence is a concern for most clinicians on the response.
However, inflammation turnaround can be rather quick com-
pared to other methods of IDILI.The significant drawback to
inflammation assays is the complexity. Commonmethods for
quantifying cytokine levels include ELISA and RT-PCR [163].
Due to toxicity occurrence coming from the immune system
rather than the liver, multiple cell systems and pathways need
to be monitored to determine the dysregulated cytokines.
Yano et al. attempted to look at the complexity of this
issue by stimulating inflammation in mouse livers [163].
They added drugs at known concentrations and measured
cytokine levels from mouse models to compare with the
current elevations in standard liver biomarkers ALT andAST.
Additionally, liver inflammation markers were compared in
in vitro monocyte cultures with and without the presence of
heat-inactivated HLMs by observing gene expression. Ulti-
mately, the results showed a time dependent responsiveness
towards cytokine development, with several of the elevated
proinflammatory markers (IL-1𝛽) clearly elevated within a
24-hour time window. Additionally, a transcription factor
that promotes inflammation that is also found in plasma,
high-mobility group protein B1 (HMGB1), was only found in
high quantities of drugs that are considered hazardous to the
liver.However, the biggest take awaywas the combined effects
on the expression of MRP8, MRP9, IL-1𝛽, and cryopyrin
(NALP3), and receptor for advanced glycation end products
(RAGE) would be elevated in the presence of drugs with
increased susceptibility to liver injury. All of these markers
are direct results of upregulation of the nuclear factor kappa
B (Nf-𝜅B) pathway.
There are several other assays besides direct quantifica-
tion cytokine levels. Master transcriptional regulators may
become a target for measuring specific lymphocyte activity
[115]. By measuring the levels of master transcriptional
regulators, scientists and clinicians have ideas of which cells
are proliferating andwhich pathways are stimulated. Another
test that can be used to assess drug toxicity is the lymphocyte
transformation test (LTT) [121, 165]. Here, cells proliferate in
response to the presence of particular antigens or drugs.
Additionally, flow cytometry can be used to quantify
adverse behavior in lymphocytes. It has been used to quantify
the presence of KCs and other cells that are involved in
inflammation-based toxicity [166], cytokine synthesis during
inflammation due to drug allergy [165], and the upregulation
of cluster of differentiation 69 (CD69) [165], a biomarker for
inflammation. Thus, injury can be assessed from in vivo and
in vitro models using flow cytometry.
In addition to drug metabolite quantification, meta-
bolism is a method for specifying immune cell activity.
Broadly, lymphocytes can be categorized based on aerobic
versus anaerobic glycolysis and whether or not oxidative
phosphorylation is taking place. The presence of aerobic
glycolysis without oxidative phosphorylation indicates the
increased activity of cells often found at the site of inflam-
mation, including neutrophils and KCs.
Cytokine knockouts have been used to monitor the
potential for ADRs in mouse and rat models. Common
knockouts that have been used to increase susceptibility to
IDILI include TNFR1 [108, 167], IL-13 [108, 168], and double
knockouts of IL-4 and IL-10 [108, 169]. In addition, IFN-𝛾
and toll-like receptor 9 (TLR9) individual knockouts seem to
decrease the susceptibility to IDILI [108]. In addition, while
the double knockout of IL-4 and IL-10 increases susceptibility
to ADRs, having a triple knockout of IL-4, IL-6, and IL-10
decreases susceptibility to IDILI [108, 169].
3.6. Genetic Regulation and Clustering. Creating genetic
profile maps can give a diversified predictability of IADRs.
Focus has been maintained on clusters of simultaneously
regulated genes [170, 171] or genes that could potentially
contribute towards IDILI [117]. Aside from genetic profiling,
only flow cytometry may be able to predict IADRs due
to HLA haplotypes [172], providing a necessary function
for predicting some mechanisms of IDILI. Clustering in
particular is important for assessment of commonly reg-
ulated genes and finding mutations within pathways. Tar-
gets for clustering analysis include xenobiotic metabolism,
bioenergetics, and mechanisms for inflammation and injury
[173]. Another target for genomic analysis is study of the
peroxisome proliferator-activated receptors (PPARs), which
are nuclear receptor proteins that control for transcription
of various enzymes involved in drug metabolism [60, 174].
Additionally, the AmpliChip CYP450 Test has been devel-
oped to detect CYP450 polymorphisms [175, 176].While gene
regulation can give indication towards missing enzymes or
downregulated pathways, clusters do not necessarily directly
correlate with protein expression or activity at either theDNA
or the RNA level as posttranscriptional modifications and
RNA degradation may occur. Even so, models that focus on
pathway regulation and gene analysis related to mechanisms
of injury can be good predictors of idiosyncratic compounds
[170, 177].
3.7. Predictive Models. While focus has been given towards
in vitro and in vivo test, computational results can rule out
a significant amount of drugs that have toxic potential. Of
particular importance is the prediction of reactive metabolite
formation [178] and how those metabolites may interact with
intracellular molecules [31, 179], or looking at drugs that
affect major regulatory molecules for drug metabolism [180,
181]. These models, while maintaining importance towards
predicting general ADRs,may also be used if certain classes of
compounds create toxicity for individuals with any clinically
relevant polymorphisms.
4. Towards Integrative Platforms for
Comprehensive IADR Predictability
While several of the current systems and assays emphasize
detection of single mechanisms for hepatotoxicity, many of
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the current in vitro systems fall short at generating complete
individual profiles for predicting IADRs. While in vivo
models can be used to generate comprehensive profiles for
ADRs and simultaneous events, they generally have poor
predictability and are more expensive than in vitro assays
[150]. The rest of this review will focus on developing
in vitro and ex vivo cellular models that can be used to
assess cumulative idiosyncratic potential with applications in
diagnosing idiosyncratic potential and drug development.
4.1. Controlled DME Expression Systems. Significant advan-
tages of utilizing hepatomas or immortalized cell lines are the
well-characterized expression of proteins from these cell lines
and the affordability they present for clinical and industrial
tests. While hepatocytes contain many of the significant
proteins for drug metabolism, maintenance of these cultures
is expensive and often the cells will lose their in vivo protein
expression hours after being cultured. Thus, controlling the
expression of DMEs, transporters, and antioxidant proteins
via manipulation of the genome in immortalized cell lines
provides a cost-effective and reproduciblemethod for charac-
terizing idiosyncratic potential. Additionally, using cells that
either have expressions that can be easily altered or adequately
reflect in vivo behavior of hepatocytes is the most important
for any in vitro toxicity assay.
Among the most utilized forms of transformable liver
cell lines are epithelial cells transformed with SV40 large
T antigen (THLE cells). These cells have very low expres-
sion of phase I and phase II DMEs, making them ideally
suited for transducing genes that express DMEs [182]. Viral
transduction can be readily performed on these cells to
express the desired DMEs. Kwon et al. successfully trans-
duced recombinant adenoviruses expressing several clinically
relevant CYP450 isoforms into THLE-2 cells on a miniatur-
ized platform that is effective at generating dose-response
curves for tested therapeutics [183]. Various combinations of
DMEs expressed in THLE-2 cells on the chip can be used to
potentially simulate systematic compound metabolism and
toxicity, including idiosyncratic ADRs [183]. Thompson et al.
also used THLE-2 cells transformed with CYP450 enzymes
to successfully assess idiosyncratic risk of several drugs
[157]. While this approach allows for tunability in enzymatic
expression for several of the key DMEs, using compounds or
short hairpin RNAs (shRNAs) to inhibit activity of specific
DMEs within hepatic cells is also a reliable approach [184].
Besides THLE cells, HepaRG have been used to quantify
drugmetabolic activity. Unlikemost other cell lines, HepaRG
cells are derived from progenitor cells and retain much of
the activity of in vivo human hepatocyte cultures, including
CYP450 activities [136]. While not as easily transformable as
the THLE cell expression system, HepaRG cells have some
tunability with expression of clinically relevant sources of
IDILI [185, 186]. Anthe´rieu et al. induced differentiation in
HepaRG cells towards successfully mimicking hepatocyte
behavior, including both phase I and phase II DME activity
[187]. As illustrated by Mueller et al., HepaRG cells also have
the potential for 3D growth in hanging droplet experiments,
and activity of critical enzymes was increased compared to
monolayer controls [188]. This is not to limit cells used for
viral transduction to affect DME expression, as HepG2 have
also been successfully transduced with adenoviral vectors
containing DNA coding for the expression of CYP450s [189].
4.2. Hepatic Coculture Systems. Liver coculture systems pro-
vide the advantage of giving a more complete profile of
liver behavior in the presence of drugs. Since the liver
contains multiple cell types, the coculture system allows
examination of the effects of drugs on different functions.
While the liver is primarily composed of hepatocytes, there
are other cells present, including several different kinds of
lymphocytes, sinusoidal endothelial cells, and stellate cells
[190]. In addition, the liver is organized based on proximity to
blood vessels. Cells closer the portal vein aremore involved in
oxidative metabolism, 𝛽-oxidation of fatty acids, ureagenesis,
and gluconeogenesis, whereas cells further frommajor blood
vessels are involved in biotransformation of drugs, glutamine
synthesis, lipid synthesis, and glycolysis [191]. As a result,
development of models for liver structure in hopes for
predicting idiosyncratic ADRs is a complex process.
Kostadinova et al. implemented a coculture system by
using porous layered nylon scaffolds designed to fit 24-
well plates, which allowed the cells to generate their own
3D matrix and growth factors by expansion between the
pores (Figure 6(a)) [192]. Additionally, this scaffold had
smaller pores to allow for nutrient regeneration and removal.
Cells cultured on this scaffold included hepatocytes, stellate
cells, KCs, and endothelial cells. Ultimately, this scaffold
was successful at maintaining in vivo conditions for normal
liver function for eleven weeks and was able to induce
proinflammatory cytokine production via addition of LPS
to scaffolds. Additionally, CYP450 assays and drug uptake
were effectivelymeasured in this system to account for several
mechanisms that an affect idiosyncratic responses.While this
system utilized a small scale, moderate throughput design,
scaling down for 96-well and 384-well plate assays would be
difficult due to the maneuverability of the scaffold.
Novik et al. present a coculture system that utilizes
microfluidic cocultures of hepatocytes and nonparenchymal
cells (NPCs) for clearance studies (Figure 6(b)) [193]. The
advantage of this system is that there is tunability in O2
parameters and flow rates, which is often missing in con-
ventional high-throughput screens. Novik et al. were able
to assess that phase I DME activity was elevated in the
presence of flowed cocultures compared to static cultures
and cultures with just hepatocytes. Additionally, the bile
canaliculi formation was successfully imaged to indicate that
transporter activity could be measured. However, there are
limits to flow systems for high-throughput detection, making
this particular system less advantageous for industrial use.
Several groups have implemented fibroblasts to facilitate
the creation of amicroenvironment that best mimics the liver
(Figure 6(c)). Khetani et al. implemented micropatterned
cocultures using fibroblasts [196]. Ultimately, while assays
restored some liver functions, there were several false neg-
atives with detecting compound toxicity, owing to the lack of
diversity and monolayer culture used for these cells. Wang et
al. micropatterned cocultures like Khetani et al., but utilize
general stromal cells instead of fibroblasts, measuring their
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Figure 6: Hepatic cell coculture systems with applications in
hepatotoxicity: (a) porous nylon membrane scaffold system [192],
(b) the microfluidic system [193, 194], and (c) micropatterned
hepatic cocultures [195].
results by quantifying circulating metabolites two and seven
days after incubation [197]. While success rates were higher
for detecting phase I and phase II metabolites compared to
microsome analysis or suspension cultures, toxicity results
were accurately predicted only about 70% of the time in
two-day cultures and 80–85% of the time in week-long
cultures. Thus, cocultures with fibroblasts in the absence of
KCs, stellate cells, and endothelial cells may not be ideally
suited for drug metabolism studies. More recently, Rose et al.
have developed a system using plated hepatocytes cocultured
with KCs to model the inflammation response within a 48-
well collagen-coated plate [132]. The group was successful
in measuring the concentrated immune response as well
as CYP3A activity using the previously mentioned luciferin
substrate [132].
Disadvantages of coculture platforms involve the com-
plexity of the scaffolds to accurately mimic the in vitro liver
environment, as well miniaturization being limited due to the
number of cells needed to accurately determine toxic effects.
The assay miniaturization is of particular importance with
microfluidic platforms and the removable inserts, as this also
impacts scalability and cost. Even integrating all cell types
on a 96-well plate platform is challenging because decreasing
the number of cells limits the interaction observed between
different cell types. Thus, size of culture optimization should
be considered when designing small scale liver tissues for
toxicity testing.
4.3. Stem Cells for Modeling DILI. Besides coculture plat-
forms, stem cells have become a larger part of the inves-
tigation into mechanisms that cause DILI and ADRs. In
particular, the use of induced pluripotent stem cells (iPSCs)
can be used to generate the necessary cell types to mimic the
adult liver and model disease states. In iPSCs, adult somatic
cells are reverted to behaving like embryonic stem cells
(ESCs) via introduction of several key transcription factors
[198]. While iPSCs require dedifferentiation with subsequent
redifferentiation to derive appropriate cell lines, they provide
an innovative way to both model liver disease and assess
how certain polymorphismsmay affect drug metabolism and
disposition in vitro. Additionally, human iPSCs (hiPSCs)
have a significant amount of commercial availability for
applications in liver toxicity testing and have the potential to
be used in coculture with hepatocytes and fibroblasts to give
an accurate model for predicting potential liver toxicity [199–
201].
It is becomingmore important that the role of iPSCs is not
only to derive hepatocyte-like cells, but also to recapitulate
their function and potential polymorphisms to generate
accuratemodels. Szkolnicka et al. have recently demonstrated
the ability of redifferentiated iPSCs to express CYP1A and
CYP3ADMEs and express similar responses to drugs as com-
pared to cryopreserved hepatocytes cultured in vitro [202].
Individualized toxicity assessments have been completed by
various groups as Choi et al. used patient-specific cell lines
for individuals deficient in the alpha-1 antitrypsin (A1AT),
a protease inhibitor that when absent has been correlated
with liver cirrhosis and heptocellular carcinoma [203]. While
maintaining levels of expression is an ongoing issue in the
field of using stem cells and iPSCs in particular, there has
been recent progress made towards having redifferentiated
cells express appropriate levels of key DMEs to be used as
models in drug metabolism [204].
4.4. Precision-Cut Liver Slices. As an alternative to standard
in vitro models, precision-cut liver slices can be studied to
determine the interactions of various cells in the liver in
order to recapitulate conditions that can lead to IDILI. The
main advantage of this ex vivo technique is that with all
cells present, the goal of coculture is achieved without recon-
structing the entire liver from the bottom up. Additionally,
most DME and transporter expression are preserved during
the toxicity testing [205]. Hadi et al. have demonstrated
this use for detecting inflammation-induced liver injury
while quantifying the levels of GSH and proinflammatory
cytokines inmouse and human-derived liver slices [156, 206].
In addition to ADRs, liver disease states can be modeled,
ranging from fibrosis to obesity [207, 208]. The disadvantage
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of this technique is that because precision-cut liver slices need
to be obtained from whole organisms, surgery or sacrifice of
specimens is required, and achieving HTS for adequate drug
modeling is difficult. While these are issues, precision-cut
liver slices do provide an adequate way to model liver disease
states.
5. Summary
With at least six general causes that have been potentially
tied to IADRs, the need for predicting IADRs before in vivo
experiments is critical. While individual drugs that might
induce inflammation or have variant metabolism based on
CYP450 expression are generally predicted before clinical
trials, less focus has been give towards other potential theories
regarding IADRs. There are currently assays available for
high-throughput applications that can be used for predicting
certain IADRs based on the individually described mecha-
nisms. Simulating simultaneous idiosyncratic events requires
platforms that can control the behavior of multiple events
at once, or ones that can mimic the in vivo environment
of the human liver. Future research should be focused on
developing high-throughput platforms and utilizing assays
that can predict ADRs in vitro.
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